Researchers sought to determine whether there were long-term benefits for patients with hematologic malignancies treated with allo-HSCT and omidubicel.
Researchers sought to determine whether adding eprenetapopt to maintenance azacitidine after HCT would be effective in patients with AML or MDS.
Researchers sought to determine the reasons for a disparity in patients who receive CAR-T therapy.
There was no significant difference in transplant-related mortality or overall survival.
The approach resulted in low rates of graft failure, viral infections, and relapse.
Researchers sought to determine the costs of care and health resource use of patients with hematologic malignancies undergoing allo-HCT.
Steroid-refractory acute GVHD is associated with high mortality rates in pediatric patients, despite second-line treatment.
Among patients with Abn1q, those who received bortezomib-based maintenance had significantly worse progression-free survival and overall survival.
The 1-year progression-free survival rate was 45%, and the 1-year overall survival rate was 59%.
After triple-class exposure, patients received more than 50 unique treatment regimens.
